[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE236993T1 - ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR - Google Patents

ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR

Info

Publication number
ATE236993T1
ATE236993T1 AT95938608T AT95938608T ATE236993T1 AT E236993 T1 ATE236993 T1 AT E236993T1 AT 95938608 T AT95938608 T AT 95938608T AT 95938608 T AT95938608 T AT 95938608T AT E236993 T1 ATE236993 T1 AT E236993T1
Authority
AT
Austria
Prior art keywords
von willebrand
willebrand factor
monoclonal antibodies
directed against
antibodies directed
Prior art date
Application number
AT95938608T
Other languages
German (de)
Inventor
Mitsuyo Nagano
Hiroshi Yamamoto
Morikazu Kito
Ryota Yoshimoto
Tsuyoshi Kobayashi
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE236993T1 publication Critical patent/ATE236993T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent. <IMAGE>
AT95938608T 1994-11-30 1995-11-29 ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR ATE236993T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29707094 1994-11-30
PCT/JP1995/002435 WO1996017078A1 (en) 1994-11-30 1995-11-29 Antithrombotic agent and anti-von willebrand factor monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE236993T1 true ATE236993T1 (en) 2003-04-15

Family

ID=17841828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938608T ATE236993T1 (en) 1994-11-30 1995-11-29 ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR

Country Status (13)

Country Link
US (3) US5916805A (en)
EP (1) EP0795608B1 (en)
JP (1) JP3331377B2 (en)
KR (1) KR100406072B1 (en)
CN (1) CN1254275C (en)
AT (1) ATE236993T1 (en)
DE (1) DE69530316T2 (en)
DK (1) DK0795608T3 (en)
ES (1) ES2197210T3 (en)
FI (1) FI119734B (en)
NO (1) NO319738B1 (en)
PT (1) PT795608E (en)
WO (1) WO1996017078A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236993T1 (en) * 1994-11-30 2003-04-15 Ajinomoto Kk ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
JP2002529373A (en) * 1998-10-23 2002-09-10 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド Conformation-specific anti-von Willebrand factor antibody
CN1198198C (en) * 2001-02-27 2005-04-20 索尼公司 Character input method and unit
JP2005298336A (en) * 2002-01-29 2005-10-27 Ajinomoto Co Inc Inflammatory disease-treating medicine
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
JPWO2004011030A1 (en) * 2002-07-29 2005-11-24 味の素株式会社 Pharmaceutical composition for the treatment of thrombocytopenia
AU2003251238A1 (en) * 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
MXPA05004955A (en) * 2002-11-08 2005-11-17 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor.
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
BRPI0316092B8 (en) * 2002-11-08 2021-05-25 Ablynx Nv single domain antibodies directed against tumor necrosis factor alpha and uses for them
US20070178082A1 (en) * 2002-11-08 2007-08-02 Ablynx N.V. Stabilized single domain antibodies
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
NZ576284A (en) * 2003-01-10 2010-07-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
CN1323713C (en) * 2003-07-07 2007-07-04 张新侯 Novel usage of soluble P-lectin and anthrax lethal toxin
JP2008512097A (en) * 2004-09-07 2008-04-24 アーケミックス コーポレイション Aptamer medicinal chemistry
MX2007002772A (en) 2004-09-07 2008-03-05 Archemix Corp Aptamers to von willebrand factor and their use as thrombotic disease therapeutics.
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20080003617A1 (en) * 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
PL1836500T3 (en) 2005-01-14 2010-12-31 Ablynx Nv METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
PT2444424T (en) 2005-05-20 2018-11-09 Ablynx Nv Improved nanobodies tm for the treatment of aggregation-mediated disorders
JP5505853B2 (en) 2007-02-13 2014-05-28 味の素株式会社 Virus inactivation method using slightly acidic arginine as an additive
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
AR070141A1 (en) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR
CA2718081A1 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
CN102089319B (en) 2008-05-08 2013-11-13 味之素株式会社 Protein reforming method
CN102532316B (en) * 2010-12-24 2014-06-18 神州细胞工程有限公司 Anti-vWF (von Willebrand factor) monoclonal antibody and application thereof
IN2014CN00436A (en) 2011-06-23 2015-04-03 Ajinomoto Kk
EP3084437B1 (en) * 2013-12-18 2018-02-28 Siemens Healthcare Diagnostics Inc. Detection of endothelial disease
WO2015158851A1 (en) * 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
CA3145453A1 (en) 2019-07-01 2021-01-07 Tonix Pharma Limited Anti-cd154 antibodies and uses thereof
US20240059781A1 (en) 2021-01-06 2024-02-22 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202264A (en) * 1989-10-27 1993-04-13 Health Research, Incorporated ELISA using multi-species antibodies for detection of von Willebrand factor in multiple species
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
ATE236993T1 (en) * 1994-11-30 2003-04-15 Ajinomoto Kk ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR
AU724579B2 (en) 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor

Also Published As

Publication number Publication date
ES2197210T3 (en) 2004-01-01
PT795608E (en) 2003-08-29
DE69530316D1 (en) 2003-05-15
EP0795608B1 (en) 2003-04-09
NO319738B1 (en) 2005-09-12
FI972279A0 (en) 1997-05-29
FI972279A (en) 1997-07-29
CN1254275C (en) 2006-05-03
WO1996017078A1 (en) 1996-06-06
JP3331377B2 (en) 2002-10-07
KR100406072B1 (en) 2004-03-30
US6280731B1 (en) 2001-08-28
DK0795608T3 (en) 2003-07-21
EP0795608A4 (en) 2001-11-28
NO972253D0 (en) 1997-05-16
US20020028204A1 (en) 2002-03-07
DE69530316T2 (en) 2004-02-12
EP0795608A1 (en) 1997-09-17
NO972253L (en) 1997-07-29
US6793920B2 (en) 2004-09-21
CN1174575A (en) 1998-02-25
US5916805A (en) 1999-06-29
FI119734B (en) 2009-02-27

Similar Documents

Publication Publication Date Title
ATE236993T1 (en) ANTITHROMBOSIS AGENTS AND MONOCLONAL ANTIBODIES DIRECTED AGAINST THE VON WILLEBRAND FACTOR
TR199801180T2 (en) New compounds with analgesic effect.
ES2182357T3 (en) NEW USE OF BUDESONIDE AND FORMOTEROL.
MX9204268A (en) A COMPOSITION FOR THE PROLONGED AND CONTROLLED RELEASE OF MEDICINAL SUBSTANCES AND A PROCESS TO PREPARE THE SAME.
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
ATE340590T1 (en) RECONSTITUTED HUMAN ANTIBODY DIRECTED AGAINST HUMAN INTERLEUKIN-8
DE69738000D1 (en) New pharmaceutical formulation containing budesonide
CO4290432A1 (en) NEW DERIVATIVES OF PIRAZINACARBOXAMIDA, ITS PREPARATION AND ITS USE IN MEDICINES.
BR9406025A (en) Composition for non-aerosol shaving
IT1281188B1 (en) COMPOSITION TO PREVENT AND TREAT INFLAMMATION WITH IMMUNOGLOBULIN A.
ATE283704T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CS-866 AND INSULIN RESISTANCE IMPROVEMENT AGENTS AND THE USE THEREOF FOR THE TREATMENT OF ARTERIOSCLEROSIS AND XANTHOMA
SE9401540D0 (en) Oral hygiene composition
FR2656214B1 (en) DYNAMIC FRAMEWORK OF RACHIS OSTEOSYNTHESIS.
NZ227812A (en) A medicament useful in reducing an immunoglobulin e response comprising as active ingredient as antagonist to human interleukin-4; and method of use
ATE83376T1 (en) QUINOLINYL ETHER TETRAZOLES AS A MEDICATION FOR THE TREATMENT OF HYPERSENSITIVE DISEASES.
BR9509975A (en) Pharmaceutical formulation
ATE478681T1 (en) USE OF POLYCLONAL ANTI-HIV GOAT SERA AS A THERAPEUTIC AGENT
SE9402880D0 (en) New peptide derivatives
ES2105605T3 (en) TAQUIQUININE ANTAGONISTS, THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS.
DE69422615D1 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
TR199801184T2 (en) New compounds with analgesic action.
KR930019224A (en) Abortion Hazard Remedy
DK0437225T3 (en) Topical preparations
FR2714603B1 (en) Dermatological composition and its use for the preparation of a medicament.
CA2206423A1 (en) Antithrombotic agent and anti-von willebrand factor monoclonal antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0795608

Country of ref document: EP